Table 2. Shift of the ED50 values for the antinociceptive activity of ketorolac and celecoxib in algesimeter tests of mice.

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug** | Shift in WT | Shift in FHP-I | Shift in FHP-II |
| *Ketorolac* | *1.00* | *1.00* | *1.00* |
| Plus NTX | 1.36 | 1.52 | 1.03 |
| Plus NTI | 1.41 | 1.72 | 1.04 |
| Plus nor-BNI | 1.87 | 1.70 | 1.06 |
| *Celecoxib* | *1.00* | *1.00* | *1.00* |
| Plus NTX | 1.07 | 1.03 | 1.83 |
| Plus NTI | 1.11 | 1.00 | 1.52 |
| Plus nor-BNI | 1.04 | 1.05 | 1.41 |

The shift values is the ratio of values of ED50 before and after the treatment with the opioid antagonist. WT: acetic acid writhing, FHP-I: formalin hind paw, phase I, FHP-II: formalin hind paw, phase II. NTX: naltrexone, NTI: naltrindole, nor-BNI: nor-binaltorphimine. The number of mice for each group was 12.